The principal aim of this project was to investigate mechanisms of drug resistance in Trypanosoma brucei, the causative agent of disease in humans (sleeping sickness) and livestock (nagana), which affects large areas of sub-Saharan Africa. By understanding the mechanisms of resistance, the useful life of current therapies (of which there are only a few) may be extended, diagnostics to identify resistant parasites could be developed and the design of novel therapies aided. We therefore developed parasites with high levels of resistance to the clinically important drug pentamidine, which is the first-line treatment for early stage West African sleeping sickness and is closely related to the main veterinary treatment diminazene aceturate (Bere...
The availability of genome sequence data has facilitated the development of high-throughput genetic ...
SCYX-7158, an oxaborole, is currently in Phase I clinical trials for the treatment of human African ...
The concept of disease-specific chemotherapy was developed a century ago. Dyes and arsenical compoun...
The principal aim of this project was to investigate mechanisms of drug resistance in Trypanosoma br...
Two parasitic trypanosomatids, T. b. gambieme and T. b. rhodesieme, are responsible for around 150,0...
Drug resistance in pathogenic protozoa is very often caused by changes to the ‘transportome’ of the ...
Objectives Trypanosoma brucei drug transporters include the TbAT1/P2 aminopurine transporter and the...
The trypanosomes cause two neglected tropical diseases, Chagas disease in the Americas and African t...
Human African trypanosomiasis (HAT), a lethal disease caused by infection with Trypanosoma brucei rh...
The concept of disease-specific chemotherapy was developed a century ago. Dyes and arsenical compoun...
Melarsoprol and pentamidine represent the two main classes of drugs, the arsenicals and diamidines, ...
Trypanosoma brucei comprise the causative agents of sleeping sickness, T. b. gambiense and T. b. rho...
Trypanosoma brucei comprise the causative agents of sleeping sickness, T. b. gambiense and T. b. rho...
African trypanosomes are highly divergent from their metazoan hosts, and as part of adaptation to a ...
The arsenal of drugs used to treat leishmaniasis, caused by Leishmania spp., is limited and beset by...
The availability of genome sequence data has facilitated the development of high-throughput genetic ...
SCYX-7158, an oxaborole, is currently in Phase I clinical trials for the treatment of human African ...
The concept of disease-specific chemotherapy was developed a century ago. Dyes and arsenical compoun...
The principal aim of this project was to investigate mechanisms of drug resistance in Trypanosoma br...
Two parasitic trypanosomatids, T. b. gambieme and T. b. rhodesieme, are responsible for around 150,0...
Drug resistance in pathogenic protozoa is very often caused by changes to the ‘transportome’ of the ...
Objectives Trypanosoma brucei drug transporters include the TbAT1/P2 aminopurine transporter and the...
The trypanosomes cause two neglected tropical diseases, Chagas disease in the Americas and African t...
Human African trypanosomiasis (HAT), a lethal disease caused by infection with Trypanosoma brucei rh...
The concept of disease-specific chemotherapy was developed a century ago. Dyes and arsenical compoun...
Melarsoprol and pentamidine represent the two main classes of drugs, the arsenicals and diamidines, ...
Trypanosoma brucei comprise the causative agents of sleeping sickness, T. b. gambiense and T. b. rho...
Trypanosoma brucei comprise the causative agents of sleeping sickness, T. b. gambiense and T. b. rho...
African trypanosomes are highly divergent from their metazoan hosts, and as part of adaptation to a ...
The arsenal of drugs used to treat leishmaniasis, caused by Leishmania spp., is limited and beset by...
The availability of genome sequence data has facilitated the development of high-throughput genetic ...
SCYX-7158, an oxaborole, is currently in Phase I clinical trials for the treatment of human African ...
The concept of disease-specific chemotherapy was developed a century ago. Dyes and arsenical compoun...